Anti-Mouse CD183 (Clone CXCR3-173) – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD183 (Clone CXCR3-173) – Purified in vivo PLATINUM™ Functional Grade
Product No.: C796
Clone CXCR3-173 Target CXCR3 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CXCR3G, protein-coupled receptor 9 (GPR9), CKR-L2, IP10 receptor (IP10-R), Mig receptor (Mig-R ) Isotype IgG Applications FC , in vivo , N |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Armenian Hamster Recommended Dilution Buffer Immunogen Mouse N-terminus of CXCR3 Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco FC Additional Applications Reported In Literature ? N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity CXCR3-173 activity is directed against murine CD183 (CXCR3). Background CXCR3 (CD183) is a chemokine receptor that binds to three ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC), that are induced by IFNγ, -α/β, or other proinflammatory cytokines1. CXCR3 is important for natural killer (NK) cell-dependent priming of CD4+ T cells in lymph nodes2, host responses to infection3, and CD4+ T cell responses to allografts4,5.
CXCR3-173 was generated by immunizing Armenian hamsters with a peptide sequence unique to mouse CXCR3 which encompasses amino acids 1-376,7. Hamsters were tested by ELISA for seropositivity against CXCR3 peptide and hybridomas were generated, screened by FACS, purified, and tested for: staining, CXCR3 blockade in vitro, and endotoxin levels6. CXCR3-173 detects the native form of CXCR3, and therefore does not work in Western blotting. CXCR3-173 has potential use in immunotherapeutic approaches to inhibit transplant rejection and immune related diseases6. In vitro, CXCR3-173 blocks chemotaxis in response to CXCL10 or CXCL11 but not CXCL9. In vivo, CXCR3-173 prolongs both cardiac and islet allograft survival in a manner further enhanced by rapamycin. Antigen Distribution CXCL3 is expressed on primary memory phenotype CD4+ and CD8+ T cells, naturally occurring CD4+CD25+ Foxp3+ regulatory T cells, natural killer (NK) T cells, and approximately 25% of NK cells. CXCR3-173 recognizes an epitope of CXCR3 expressed on the surface of activated mouse splenocytes. NCBI Gene Bank ID UniProt.org Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone CXCR3-173 is commonly used in vivo in mice primarily as a neutralizing (blocking) monoclonal antibody targeting the chemokine receptor CXCR3 (CD183), which is expressed on subsets of T cells and NK cells. Its most well-established in vivo applications are as follows:
Key details on mechanism and use:
Other experimental applications:
Summary Table: Common In Vivo Applications of CXCR3-173 in Mice
In summary, CXCR3-173 is a well-established tool for in vivo blockade of CXCR3 functions in mice, enabling mechanistic studies of immune cell recruitment and the development of therapeutic strategies in transplantation, autoimmunity, and tumor models. Commonly used antibodies or proteins paired with CXCR3-173 in experimental literature primarily target cellular markers for the characterization and functional analysis of immune cell subsets, especially in the context of transplantation, inflammation, and immune modulation models. Key antibodies and proteins frequently used with CXCR3-173 include:
To summarize, the most commonly paired antibodies/proteins with CXCR3-173 in research are those recognizing lineage (CD4, CD8, NK1.1, CD3), regulatory (CD25, Foxp3), and activation/memory (CD44, CD69, CD62L) markers, as well as chemokine ligands and immunomodulators like rapamycin. This multi-marker approach allows for comprehensive immunophenotyping and mechanistic studies in murine immune models. Clone CXCR3-173 is a well-characterized, non-depleting, function-blocking monoclonal antibody that specifically targets murine CXCR3, and it is widely cited in scientific literature for its critical role in dissecting CXCR3 function, particularly in immune cell trafficking, transplantation tolerance, tumor immunology, and models of inflammatory disease. Key findings from CXCR3-173 citations include:
In summary: Scientific literature consistently recognizes CXCR3-173 as a powerful, non-depleting, function-blocking antibody to dissect CXCR3’s role in immune cell trafficking—particularly to study mechanisms of transplant rejection, immune-mediated diseases, and tissue inflammation in mice. It is regarded as a gold-standard reagent for in vivo and ex vivo functional studies of murine CXCR3. Dosing regimens for clone CXCR3-173 in mouse models vary based on the experimental purpose, mouse strain, and disease context, but typical doses range from 40 μg to 1 mg per mouse and are administered either as single or multiple intraperitoneal (i.p.) injections over periods from days to weeks.
In summary, the most common dosing pattern for CXCR3-173 in mice falls between 40 μg and 1 mg per dose, administered via intraperitoneal injection, with adjustments for dose frequency and total duration according to disease model and experimental goals. If you seek a specific disease context (autoimmunity, transplantation, inflammation), more tailored regimens may exist in specialized protocols. References & Citations1. Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018.
2. Martin-Fontecha A, Thomsen LL, Brett S, et al. Nat Immunol. 5: 1260-1265. 2004. 3. Khan IA, MacLean JA, Lee FS, et al. Immunity. 12: 483-494. 2000. 4. Hancock WW, Lu B, Gao W, et al. J Exp Med. 192: 1515-1520. 2000. 5. Hancock WW, Gao W, Csizmadia V, et al. J Exp Med. 193: 975-980. 2001. 6. Uppaluri R, Sheehan KC, Wang L, et al. Transplantation. 86(1):137-147. 2008. 7. Krug A, Uppaluri R, Facchetti F, et al. J Immunol. 169(11):6079-6083. 2002. Technical ProtocolsCertificate of Analysis |
Formats Available
